Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fattom

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Infection and Immunity|February 1, 1992
Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionateA Fattom, J Shiloach, D Bryla, et al.
Infection and Immunity|July 1, 1990
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin AA Fattom, R Schneerson, S C Szu, et al.
Journal of the American Society of Nephrology : JASN|February 1, 1996
Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysisP G Welch, A Fattom, J Moore, et al.
Current Topics in Microbiology and Immunology|January 1, 1989
Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugatesJ B Robbins, R Schneerson, S C Szu, et al.
Vaccine|October 1, 1995
Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharidesA Fattom, X Li, Y H Cho, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1991
Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPLR Schneerson, A Fattom, S C Szu, et al.
Infection and Immunity|September 1, 1988
Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugatesA Fattom, W F Vann, S C Szu, et al.
Infection and Immunity|March 1, 1993
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein AA Fattom, R Schneerson, D C Watson, et al.
Infection and Immunity|July 1, 1990
Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoidA Fattom, C Lue, S C Szu, et al.
Pharmacology, Biochemistry, and Behavior|January 19, 2000
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in ratsP R Pentel, D H Malin, S Ennifar, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Infection and Immunity|February 1, 1992
Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionateA Fattom, J Shiloach, D Bryla, et al.
Infection and Immunity|July 1, 1990
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin AA Fattom, R Schneerson, S C Szu, et al.
Journal of the American Society of Nephrology : JASN|February 1, 1996
Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysisP G Welch, A Fattom, J Moore, et al.
Current Topics in Microbiology and Immunology|January 1, 1989
Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugatesJ B Robbins, R Schneerson, S C Szu, et al.
Vaccine|October 1, 1995
Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharidesA Fattom, X Li, Y H Cho, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1991
Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPLR Schneerson, A Fattom, S C Szu, et al.
Infection and Immunity|September 1, 1988
Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugatesA Fattom, W F Vann, S C Szu, et al.
Infection and Immunity|March 1, 1993
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein AA Fattom, R Schneerson, D C Watson, et al.
Infection and Immunity|July 1, 1990
Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoidA Fattom, C Lue, S C Szu, et al.
Pharmacology, Biochemistry, and Behavior|January 19, 2000
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in ratsP R Pentel, D H Malin, S Ennifar, et al.
Pageof 4